Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study

被引：6

作者：

Sone, Hideyuki ^{[1
]}

Igawa, Satoshi ^{[1
]}

Kasajima, Masashi ^{[1
]}

Ishihara, Mikiko ^{[1
]}

Hiyoshi, Yasuhiro ^{[1
]}

Hosotani, Shinji ^{[1
]}

Ohe, Shuntaro ^{[1
]}

Ito, Hiroki ^{[1
]}

Kaizuka, Nobuki ^{[1
]}

Manaka, Hiroya ^{[1
]}

Fukui, Tomoya ^{[1
]}

Mitsufuji, Hisashi ^{[2
]}

Kubota, Masaru ^{[1
]}

Katagiri, Masato ^{[3
]}

Sasaki, Jiichiro ^{[4
,5
]}

Naoki, Katsuhiko ^{[1
]}

机构：

[1] Kitasato Univ, Sch Med, Dept Resp Med, Sagamihara, Kanagawa, Japan

[2] Kitasato Univ, Sch Nursing, Fundamental Nursing Dept, Sagamihara, Kanagawa, Japan

[3] Kitasato Univ, Sch Allied Hlth Sci, Med Lab, Sagamihara, Kanagawa, Japan

[4] Kitasato Univ, Sch Med, Dept Res, Sagamihara, Kanagawa, Japan

[5] Kitasato Univ, Sch Med, Dev Ctr New Med Frontiers, Sagamihara, Kanagawa, Japan

来源：

THORACIC CANCER | 2018年 / 9卷 / 10期

关键词：

Amrubicin; chemotherapy; elderly patient; small-cell lung cancer; RANDOMIZED PHASE-III; POST-PROGRESSION SURVIVAL; SYNTHETIC; 9-AMINOANTHRACYCLINE; TRIAL; JAPAN; CARBOPLATIN; TOPOTECAN; ETOPOSIDE; 2ND-LINE; SM-5887;

D O I：

10.1111/1759-7714.12833

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundPrevious studies have shown amrubicin (AMR) to be an effective second-line treatment option for small-cell lung cancer (SCLC). However, the efficacy of AMR in elderly patients with relapsed SCLC has not been sufficiently evaluated. MethodsThe medical records of elderly patients with relapsed SCLC who received AMR as second-line chemotherapy were retrospectively reviewed, and their treatment outcomes were evaluated. ResultsThirty-one patients with a median age of 72 years (22 patients with sensitive relapse and 9 with refractory relapse) were analyzed. The median number of treatment cycles was four (range: 1-10), and the response rate was 29%. The median progression-free survival (PFS) and overall survival (OS) were 5.4 and 11.6 months, respectively. The OS of 22 patients who received third-line chemotherapy was 15.5 months. The PFS (6.2 vs. 3.2 months; P = 0.002) and OS (14.8 vs. 5.7 months; P = 0.004) were significantly longer in patients with sensitive relapse than those with refractory relapse. The frequency of grade 3 or higher neutropenia was high (n = 18, 58%), while febrile neutropenia was only observed in five patients (16%). Non-hematological toxic effects were relatively mild, and pneumonitis and treatment-related deaths were not observed. ConclusionAMR may be a feasible and effective regimen for elderly patients with relapsed SCLC.

引用

页码：1279 / 1284

页数：6

共 29 条

[21] Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer:: A phase II study [J].

Quoix, E ;

Breton, JL ;

Daniel, C ;

Jacoulet, P ;

Debieuvre, D ;

Paillot, N ;

Kessler, R ;

Moreau, L ;

Coëtmeur, D ;

Lemarié, E ;

Milleron, B .

ANNALS OF ONCOLOGY, 2001, 12 (07) :957-962

[22] A Randomized Phase III Study of Single-Agent Amrubicin Vs. Carboplatin/Etoposide in Elderly Patients With Extensive-Disease Small-Cell Lung Cancer [J].

Sekine, Ikuo ;

Okamoto, Hiroaki ;

Horai, Takeshi ;

Nakagawa, Kazuhiko ;

Ohmatsu, Hironobu ;

Yokoyama, Akira ;

Katakami, Nobuyuki ;

Shibuya, Masahiko ;

Saijo, Nagahiro ;

Fukuoka, Masahiro .

CLINICAL LUNG CANCER, 2014, 15 (02) :96-102

[23] Current small cell lung cancer treatment in China [J].

Shi, Yuankai ;

Xing, Puyuan ;

Fan, Yun ;

Zhang, Xin ;

Hu, Chengping ;

Wang, Caixia ;

Liu, Xiaoqing ;

Chen, Xiaoxia ;

Zhou, Jianying ;

Wang, Mengzhao ;

Wu, Meina ;

Han, Baohui ;

Fan, Min .

THORACIC CANCER, 2015, 6 (03) :233-238

[24] Medical management of lung cancer: Experience in China [J].

Shi, Yuankai ;

Sun, Yan .

THORACIC CANCER, 2015, 6 (01) :10-16

[25] Trends in lung cancer incidence by histological type in Osaka, Japan [J].

Toyoda, Yasuhiro ;

Nakayama, Tomio ;

Ioka, Akiko ;

Tsukuma, Hideaki .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (08) :534-539

[26] Small-cell lung cancer [J].

van Meerbeeck, Jan P. ;

Fennell, Dean A. ;

De Ruysscher, Dirk K. M. .

LANCET, 2011, 378 (9804) :1741-1755

[27] Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer [J].

von Pawel, Joachim ;

Jotte, Robert ;

Spigel, David R. ;

O'Brien, Mary E. R. ;

Socinski, Mark A. ;

Mezger, Joerg ;

Steins, Martin ;

Bosquee, Leon ;

Bubis, Jeffrey ;

Nackaerts, Kristiaan ;

Trigo, Jose M. ;

Clingan, Philip ;

Schuette, Wolfgang ;

Lorigan, Paul ;

Reck, Martin ;

Domine, Manuel ;

Shepherd, Frances A. ;

Li, Shaoyi ;

Renschler, Markus F. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (35) :4012-U160

[28] Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells [J].

Yamaoka, T ;

Hanada, M ;

Ichii, S ;

Morisada, S ;

Noguchi, T ;

Yanagi, Y .

JAPANESE JOURNAL OF CANCER RESEARCH, 1998, 89 (10) :1067-1073

[29] Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study [J].

Yana, Takashi ;

Negoro, Shunichi ;

Takada, Minoru ;

Yokota, Soichiro ;

Takada, Yoshiki ;

Sugiura, Takahiko ;

Yamamoto, Hidehiko ;

Sawa, Toshiyuki ;

Kawahara, Masaaki ;

Katakami, Nobuyuki ;

Ariyoshi, Yutaka ;

Fukuoka, Masahiro .

INVESTIGATIONAL NEW DRUGS, 2007, 25 (03) :253-258

← 1 2 3 →